GT Biopharma is trading 5.7% higher at $7.07 on October 20, 2026, with no new company-specific announcement or clear catalyst identified for the move.
- The latest listed company press release is dated September 15.
- Biotech-sector strength may provide context, including Merck’s acquisition of Silence Therapeutics, but available evidence does not establish that sector activity caused the move.